13F Holdings
中文EN

OACC Oaktree Acquisition Corp. III Life Sciences

Blank Checks · Nasdaq · SEC CIK 2029769 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA2.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.2%
Debt / equity—
Current ratio0.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31
Income statement
Revenue—
Operating income-$1.20M
Net income$7.29M
EPS (diluted)—
Balance sheet
Cash & equivalents$1.43M
Current assets$1.55M
Total assets$203.11M
Current liabilities$1.30M
Total liabilities$8.32M
Shareholders' equity-$6.77M
Cash flow statement
Operating cash flow-$422,079
Investing cash flow$500,000
Financing cash flow$0

· Financial companies (banks, insurers, …) usually do not report gross profit or operating income; bank revenue is net revenue (net interest income + noninterest income), smaller than "gross interest income + noninterest income".

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.